In the 21 st century, human civilization, has witnessed three major epidemics caused by Coronaviruses namely severe acute respiratory syndrome coronavirus (SARS‑CoV) in 2003, Middle East respiratory syndrome coronavirus (MERS‑CoV) in 2012 and 2019‑novel coronavirus (2019‑nCoV) or coronavirus disease (COVID‑19) in 2019. Among these, COVID-19 has greater transmission and mortality rate. 2019‑nCoV belongs to a large family of positive sense single-stranded RNA viruses (+ssRNA) that can be isolated in different animal species. The most communal symptoms of COVID-19 include fever, cough, and shortness of breath during the incubation period (2-14 days) of infection. COVID-19 transmission is occurring from infected humans to close contact with one another through respiratory droplets, coughs, and sneezes of infected person. Moreover, the virus containing surfaces may also transmit the infection. Diagnosis is being carried out by collecting a nasopharyngeal swab or sputum specimen for detection of SARS-CoV-2 RNA by reverse-transcription polymerase chain reaction (RT-PCR). Rapid diagnosing methods are also under development which can diagnose COVID 19 in few minutes to hours. Currently, there is no specific cure or preventive therapeutics available. Hence, based upon limited in-vitro and anecdotal data, Chloroquine, or Hydroxychloroquine, Remdesivir, Lopinavir and Ritonavir are being employed in the management. Search for new specific anti-viral drugs from natural/synthetic origins is under full swing and many of them are currently used as chemotherapeutic drugs under clinical investigation. Yet, there is a strong need for development of vaccine, which may take several months to few years for the development.
Introduction: Type 2 diabetes mellitus (T2D) is a progressing polygenic disease demanding a multitargeted treatment strategy. Sargassum tenerrimum (ST) is a marine brown alga with potentially bioactive chemicals that could be used as innovative biotherapeutics for diabetes treatment. The current research examined the potential of the phlorotannin-rich fraction from S. tenerrimum (PST) to mitigate diabetes in Wistar albino rats induced with high-fat diet (HFD) and streptozotocin (STZ) administration. Methods: Diabetic rats were given PST (200 and 400 mg/kg) or metformin (250 mg/kg) orally three weeks, and followed by the measurements of insulin, glycemic factors, biological markers of oxidative stress, tumor necrosis factor-alpha (TNF-α), as well as hepatic and pancreatic histopathological changes. Results: PST treatment significantly decreased fasting blood glucose, insulin resistance, lipid profile, hepatic profile, and TNF- α levels and improved serum insulin and glucose tolerance in diabetic rats. In the skeletal muscles of diabetic rats, PST led to a significant rise in antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) reductase, and a decrease in lipid peroxidation. Furthermore, PST treatment significantly reduced pancreatic-cell damage and hepatic fatty accumulation. PST was more efficacious at 400 mg/kg exhibiting a dose-dependent effect. Conclusion: PST improves glucolipid metabolism in HFD and STZ-induced diabetic rats, probably by reducing hyperglycemia, insulin resistance, dyslipidemia, oxidative stress, inflammation, and damage to pancreatic and hepatic architectures. The findings suggest that PST has a curative impact on diabetes mellitus type 2 and represents a new subject of study for the treatment of diabetes naturally.
This study investigated how Rhus toxicodendron (RT) (6C, 30C, and 200C) can boost the immune system of BALB/c mice that were given cyclophosphamide (CPM), which is an anticancer drug that weakens the immune system. RT, known for its historical use in traditional homeopathic remedies, has demonstrated immunomodulatory and anti-inflammatory effects in various experimental models. To test the immune-boosting effects of RT, CPM (80 mg/kg) was given intraperitoneally to mice on days 4, 8, and 12 of the study but not to the normal control group. CPM-induced immunosuppression led to significant decreases in red blood cell (RBC), white blood cell (WBC), and hemoglobin (Hb) levels, and reduced spleen and thymus indices. Phagocytic activity, cytokine concentrations, and spleen architecture were also adversely affected. RT treatment, particularly at 200C, significantly ameliorated these effects, improving RBC, WBC, and Hb levels. Furthermore, RT partially prevented CPM-induced atrophy of immune organs. Treatment positively influenced cytokine production at both the protein and mRNA levels, restoring immune balance. Histopathological results confirmed that RT stimulated the immune system. The cells were more stable, and the white pulp in the spleen was arranged in a regular pattern. These findings suggest that RT may serve as an adjunctive immunostimulant therapy for conditions characterized by immunosuppression. However, further investigations in other immunocompromised states must validate these results before considering human clinical trials.
28 March 2024 in Indian Journal of Research in Homoeopathy
Background: Rhus toxicodendron (Rhus tox.) is a well-known homoeopathic medicine used to treat inflammatory disorders supported by historical and modern scientific evidence. Objective: The safety testing of 6C, 30C and 200C potencies of Rhus tox. through acute and sub-acute oral toxicity tests as per the Organisation for Economic Cooperation and Development test guidelines. Methods: For the acute oral toxicity study, Rhus tox. (2000 μL/kg) was administered to rats and observed for 14 days. For the subacute oral toxicity study, Rhus tox. (200 μL/kg) was administered for 28 days and additional recovery groups were included to monitor reversibility, persistence, or delayed occurrence of toxic effects for 14 days post-treatment. Histopathological assessments of vital organs were done to detect any signs of toxicity. Results: No mortality occurred during the acute toxicity study at a dose of 2000 μL/kg, indicating an oral LD50 of Rhus tox. >2000 μL/kg. In the sub-acute toxicity study, Rhus tox. administration for 28 days showed no adverse clinical signs, with normal weight gain and feed intake in treated animals. No adverse changes were noticed in the biochemical and haematological parameters of Rhus tox. treated rats. Furthermore, no abnormalities were observed in gross and histopathological examinations of vital organs. Conclusion: The study found that Rhus tox. in 6C, 30C and 200C potencies exhibited a safe toxicological profile, supporting its beneficial pharmacological effects.
Oxidative stress and inflammation are the most common pathologies in immune-compromised diseases and cancer treatments. The study examined the immune stimulation properties of Bryonia alba (BA) in different potencies (6C, 30C, and 200C) on a BALB/c mice model with a compromised immune system induced by cyclophosphamide (CPM) at a dose of 80 mg/kg. Seventy mice (35 males and 35 females) were randomly distributed into seven groups of 5 animals/sex. Mice treated with different potencies of BA showed notable improvements in various immune parameters, including RBC, WBC, and Hb levels, as well as thymus and phagocytic indices. Treatment also increased serum levels and splenic mRNA expression of IL-2, IL-4, TNF-α, and IFN-γ. The histopathology analysis showed that the spleen sections of the normal group exhibited intact white and red pulp. In contrast, the sections of the CPM group exhibited disrupted and atrophied white pulp. The treatment with BA maintained the spleen in a preserved state, with the white and red pulp remaining intact and a higher density of lymphocytes. The results indicate that BA could serve as a valued immunostimulant agent when administered with chemo-therapy. However, additional research is required to assess the immunostimulatory effects of BA in immune-compromised infections.
Background Rhus toxicodendron is a homoeopathic medicine introduced into the homoeopathic system by Hahnemann in 1816, and ever since, it has been used to relieve arthritis, rheumatism and skin disorders. Aim This review aimed to search the literature for the phytochemical and pharmacological investigations of homeopathic medicine Rhus tox. The assembled data of Rhus tox could be beneficial in helping researchers concentrate on the most pivotal aspects that still need to be examined. Discussion In the Homoeopathic Pharmacopoeia of India, Toxicodendron pubescens P. Mill (Atlantic poison oak) and Toxicodendron radicans (poison ivy) have been mentioned as synonyms of Rhus toxicodendron Linn. The allergic contact dermatitis caused by touching the leaves of the Toxicodendron plants is believed to give the plant its specific name. Available literature illustrated the medicinal and pharmacological potential against various inflammatory diseases, including arthritis, showing immunomodulatory and anti-neoplastic activity. Conclusion There is a need to establish evidence for the activities mentioned in the literature. The detailed knowledge regarding the mechanism of Rhus toxicodendron Linn. would help the scientific community understand the field of homeopathic medicine more closely.